Noticeably, a recent study established GXNT’s MEK-ERK1/2 inhibition in cardiac hypertrophy [44], while our study reveals how its compounds Sal B and Sen I synergistically target the upstream factor MAP3K1, providing greater mechanistic resolution of this herbal medicine's polypharmacology. The gene discussed is MAP2K7; the disease is cardiac hypertrophy.